Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (0) | Back to Search
Understanding variation in PK exposure in human dose escalation studies
- In: Poster Presentation
- At: Stockholm (Sweden) (2017)
- Type: Poster
- Poster code: P-A-105-Monday
- By: VEDIN, Charlotta (AstraZeneca, Safety and ADME translational sciences, Drug safety and metabolism, Mölndal, Sweden)
- Co-author(s): Charlotta Vedin: Safety and ADME translational sciences, Drug safety and metabolism, IMED AstraZeneca, Sweden
Katarina Breitholtz: Safety and ADME translational sciences, Drug safety and metabolism, IMED AstraZeneca, Sweden
Katherine Fenner: Safety and ADME translational sciences, Drug safety and metabolism, IMED AstraZeneca, United Kingdom
Constanze Hilgendorf: Safety and ADME translational sciences, Drug safety and metabolism, IMED AstraZeneca, Sweden
James D Clarke: Oncology DMPK, IMED AstraZeneca, United Kingdom - Abstract:
Backgrounds
In clinical dose escalation studies the pharmacokinetics of AZ1 exhibited significant variability. The variability was suggested to be caused by limited absorption and/or intestinal metabolism of AZ1.Aims
The permeability and intestinal metabolism of AZ1 were studied in Ussing chamber experiments using fresh human jejunum samples to.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 28 September 2023